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Purpose of the study
Can WHO staging, anaemia or low body mass index
(LBMI) be used to identify HIV-infected Ugandans with
CD4 counts <200 cells/μl?
Methods
From October 1995–April 2006, we screened 3,494 Ugan-
dans, aged 16 years or older, for a cross-sectional study.
We analyzed HAART-naïve HIV-infected patients with
WHO stages 1–3 who had complete data. Low BMI was
BMI<18.5 kg/m2, and anaemia a haemoglobin level<11
or 12 g/dl among women and men, respectively.
Summary of results
We analyzed 2,892 patients with median age of 32 years;
2,055 (71%) women; 1,569 (54%) WHO stage 3; 974
(34%) anaemia; 472 (16%) low BMI; and 1,242 (43%)
with CD4 counts <200 cells/μl. WHO stage 3 compared to
WHO stages 1 and 2 had sensitivity and specificity (95%
CI) of 70% (67, 72) and 57% (55, 60), respectively, to
detect CD4 counts <200 cells/μl. Anaemia had sensitivity
and specificity (95% CI) of 47% (44, 50) and 76% (74,
78), respectively. Low BMI had sensitivity and specificity
(95% CI) of 23% (20, 25) and 89% (87, 90), respectively,
against CD4 counts <200 cells/μl. WHO stage 3 or anae-
mia or low BMI had sensitivity and specificity (95% CI) of
79% (77, 81) and 50% (47, 52), respectively.
Conclusion
Only WHO stage 3 had an acceptable sensitivity to iden-
tify patients with CD4 counts of <200 cells/μl in this set-
ting; whilst specificity was modest. Other screening
strategies such as on-site low-cost CD4 testing need to be
developed to identify patients in need of HAART in rural
Africa and other resource-limited settings.
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